CoImmune® is a privately held, clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class cellular immunotherapies. Our allogeneic CAR-CIK technology platform for liquid and solid tumors is a variation on CAR-T therapy that promises enhanced efficacy with greatly reduced toxicity. Our autologous RNA-loaded dendritic cell technology for solid tumors uses amplified total tumor mRNA to program highly engineered dendritic cells to generate immune responses against neoantigens without the need to identify them.
CoImmune®, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced that preclinical models show CAR T cells engineered with OrexiCAR technology to secrete a CD47-SIRPα checkpoint blocker have improved anti-tumor activity and reverse myeloid immunosuppression in tumors. The results are published in Blood, the most highly cited …
CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced the presentation of results from a Phase I/II clinical trial evaluating CARCIK-CD19, an investigational treatment based on the company's chimeric antigen receptor (CAR) modified cytokine induced killer (CIK) cell platform, in pediatric and adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who had relapsed following hematopoietic stem cell transplantation (HSCT).
Our Products
Technology
Focused on the development and commercialization of our clinical-stage platform technologies
CAR-CIK
allogeneic CAR-CIK cells
Solid Tumors
allogeneic CAR-CIK in solid tumors
CMN-001
autologous RNA-loaded dendritic cells
0
Studies
0
Patents
0
Employees
0
Countries
Our Story
About Us
CoImmune®Inc. is a US company based in Durham North Carolina that was founded in 2019 based on its expertise in the development and manufacture of cell-based therapeutics to treat unmet medical needs including cancer, autoimmune and inflammatory diseases. CoImmune has a 20,000 sq. ft. cGMP manufacturing facility capable of supporting clinical studies from Phase 1 through Phase 3. The company is preparing to initiate its first Phase 2 clinical trial using a strategic combination of immuno-oncology therapeutics.
“All of us at CoImmune are very excited by the work we are doing with our colleagues in Italy. We are planning additional clinical trials to be conducted in the United States and Italy targeting B-ALL, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma and acute myelogenous leukemia”
